| About the author: |
A. Ye. Bogomolov, S. V. Zaikov, L. G. Kulyk, O. V. Plykanchuk |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of the study was to evaluate the effectiveness and safety of bilastine in relieving symptoms in patients aged 6–12 years with allergic rhinitis. In this prospective, randomized study, 50 patients aged 6 to 12 years with newly diagnosed allergic rhinitis and confirmed sensitization to allergens of household or pollen group participated; 46 completed the course of treatment within 4 weeks. Patients received bilastine orally at a dose of 10 mg daily for 4 weeks. Before starting treatment, the average level of severity of eye and nasal symptoms was assessed using the total nasal symptom score questionnaire for 5 days, with further assessment in 7, 14 and 28 days after starting bilastine intake. In general, at the endpoint of monitoring after 4 weeks, the reduction in the severity of symptoms was 49.1 %. A total of 89.1 % of patients (n=41) who received bilastine at a dose of 10 mg had no adverse reactions during the study. All adverse reactions were classified as mild, with headache being the most common, reported in 2 (4.3 %) cases. |
| Tags |
allergic rhinitis,children,symptomatic therapy,antihistamines,bilastine |
| Bibliography |
- Avramenko Y, Izmailova O, Shlykova O, Kaidashev I. Interleukin-26 is associated with the level of systemic inflammation and lung functions in obese and non-obese moderate-to-severe asthmatic patients. Advances in Respiratory Medicine. 2022; Vol. 90:97–108. DOI:0.5603/ARM.a2022.0006
- Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi:10.1016/j.jaci.2017.03.050
- Gogunskaya I, Zaikov S, Bogomolov A. (2020). Diagnostic parameters of in vivo (skin prick) and in vitro (ELISA) tests for determination of epidermal cat and dog allergens sensitization in patients with allergic rhinitis and atopic asthma. Georgian Medical News. 2020; 302:76–81.
- Leceta A, García A, Sologuren A, Campo C. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions. Drugs Context. 2021;10: 5–1. doi:10.7573/dic.2021-5-1
- Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73–85. doi:10.1016/j.aller.2012.03.001
- Okubo K, Gotoh M, Togawa M, Saito A, Ohashi Y. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial. Auris Nasus Larynx. 2017 Jun;44(3):294–301. doi: 10.1016/j.anl.2016.07.021.
- Rodríguez Del Río P, Rodríguez Fernández F, Ballester Asensio E, Tortajada-Girbés M. How bilastine is used to treat allergic rhinitis and urticaria in children. Immunotherapy. 2022;14(1):77–89. doi:10.2217/imt-2021-0251
- Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012;16(14):1999–2005.
- Singh Randhawa A, Mohd Noor N, Md Daud MK, Abdullah B. Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis. Front Pharmacol. 2022; 12:731201. doi:10.3389/fphar.2021.731201
- Sultész M, Horváth A, Molnár D, Katona G, Mezei G, Hirschberg A, et al. Prevalence of allergic rhinitis, related comorbidities and risk factors in schoolchildren. Allergy, asthma, and clinical immunology: official journal of the Canadian Society of Allergy and Clinical Immunology. 2020:16(1), 98. https://doi.org/10.1186/s13223-020-00495-1
- Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang de Y. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag. 2016; 12:585–597. doi:10.2147/TCRM.S105189
- Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. The New England journal of medicine, 372(5), 456–463. https://doi.org/10.1056/NEJMcp1412282
|
| Publication of the article |
«World of Medicine and Biology» №3(81), 2022 year, 031-034 pages, index UDK 612.017.3:616-079 |
| DOI |
10.26724/2079-8334-2022-3-81-31-34 |
